PURPOSE OF REVIEW: There are currently over 40 different drugs in 12 distinct classes approved in the USA to treat patients with type 2 diabetes mellitus. This review summarizes our current knowledge about potential side effects of antidiabetic therapy and attempts to apply it to a clinical practice setting. RECENT FINDINGS: Given the heterogeneity of both the patients and the disease, it is mathematically impossible to test every available drug combination in long-term outcome, prospective, randomized blinded fashion before a clinician decides which agent(s) to prescribe to a specific patient in a given situation. To complicate the clinician's dilemma, there is lack of available tests to predict an individual's response or propensity to side effects. Further, the data available are derived from small, short-term registration trials and typically focus on relative rather than absolute risks of any given drug and do not address the potential adverse outcomes if a patient's diabetes remains untreated. Clinicians have to personalize their choice of antidiabetic therapy based both on the specific characteristics of the patient in front of them (stage of diabetes and its complications, overall health status, socioeconomic situation, other medications present, desire to improve control of diabetes, etc.) and the current knowledge about the relative and absolute balance of benefits and risks of any individual medication in that specific patient. It has to be recognized that this requires constant re-evaluation as database of our experience with antidiabetic therapy expands.

Grunberger Diabetes Institute 43494 Woodward Avenue suite 208 Bloomfield Hills MI 48302 USA

Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic

Internal Medicine and Molecular Medicine and Genetics Wayne State University School of Medicine Detroit MI USA

Internal Medicine Oakland University William Beaumont School of Medicine Rochester MI USA

Zobrazit více v PubMed

Endocr Pract. 2016 Jun;22(6):753-62 PubMed

Diabetes Care. 2015 Jan;38(1):140-9 PubMed

N Engl J Med. 2013 Oct 3;369(14):1317-26 PubMed

J Clin Endocrinol Metab. 2010 Nov;95(11):4993-5002 PubMed

N Engl J Med. 2016 Jul 28;375(4):311-22 PubMed

Ann Intern Med. 2012 Nov 6;157(9):601-10 PubMed

Curr Med Res Opin. 2004 Apr;20(4):565-72 PubMed

N Engl J Med. 2016 Apr 7;374(14 ):1321-31 PubMed

J Clin Endocrinol Metab. 2010 Nov;95(11):4867-70 PubMed

Diabetologia. 2014 Jul;57(7):1320-4 PubMed

Ann Intern Med. 2016 Jun 7;164(11):740-51 PubMed

Postgrad Med. 2014 May;126(3):16-34 PubMed

Diabetes Care. 2014 Nov;37(11):3106-13 PubMed

Arch Intern Med. 1994 Nov 14;154(21):2442-8 PubMed

JAMA. 2015 Jul 21;314(3):265-77 PubMed

Diabetes Care. 2015 Feb;38(2):277-84 PubMed

Diabetologia. 1997 Dec;40(12):1492-3 PubMed

Diabetes Care. 2017 Apr;40(4):468-475 PubMed

Ann Intern Med. 2007 Sep 18;147(6):386-99 PubMed

Ann Intern Med. 2016 Jun 7;164(11):705-14 PubMed

Diabetes Care. 2011 Apr;34(4):916-22 PubMed

J Am Soc Nephrol. 2017 Jan;28(1):368-375 PubMed

Diabetes Care. 2014 Jun;37(6):1767-70 PubMed

N Engl J Med. 2011 Mar 24;364(12):1104-15 PubMed

Diabetologia. 2016 Sep;59(9):2036-9 PubMed

N Engl J Med. 2014 Feb 27;370(9):794-7 PubMed

Diabetes Care. 2004 Jun;27(6):1265-70 PubMed

Diabetologia. 2002 Feb;45(2):195-202 PubMed

Diabetes. 1970;19:Suppl:789-830 PubMed

Diabetologia. 2009 Sep;52(9):1732-44 PubMed

BMJ Open. 2016 Feb 24;6(2):e009417 PubMed

N Engl J Med. 2013 Oct 3;369(14):1327-35 PubMed

Diabetes Care. 2016 May;39(5):726-34 PubMed

Endocr Pract. 2016 Jan;22(1):84-113 PubMed

BMJ. 2011 Mar 17;342:d1309 PubMed

N Engl J Med. 2016 Jul 28;375(4):323-34 PubMed

J Clin Pharmacol. 2000 Jan;40(1):49-57 PubMed

Pancreas. 2013 Nov;42(8):1227-37 PubMed

JAMA. 2016 Jul 19;316(3):313-24 PubMed

N Engl J Med. 2015 Nov 26;373(22):2117-28 PubMed

Diab Vasc Dis Res. 2013 Jul;10(4):302-14 PubMed

N Engl J Med. 2012 Jul 26;367(4):319-28 PubMed

Metabolism. 1991 Jun;40(6):639-44 PubMed

Diabetes Obes Metab. 2011 Jan;13(1):7-18 PubMed

Expert Opin Investig Drugs. 1999 Oct;8(10):1683-1707 PubMed

Diabetes Care. 2008 Aug;31(8):1479-84 PubMed

Lancet. 2006 Sep 23;368(9541):1096-105 PubMed

Diabetes Care. 2011 May;34 Suppl 2:S244-50 PubMed

Drugs Context. 2015 Jul 09;4:212283 PubMed

Lancet Diabetes Endocrinol. 2016 May;4(5):411-9 PubMed

Diabetologia. 2012 Jul;55(7):1953-62 PubMed

J Diabetes. 2013 Sep;5(3):241-53 PubMed

Horm Metab Res. 2010 Jan;42(1):23-30 PubMed

JOP. 2013 Jan 10;14(1):81-4 PubMed

Diabetes Care. 2015 Sep;38(9):1687-93 PubMed

CMAJ. 2012 Sep 4;184(12):E675-83 PubMed

Diabetes Care. 1999 Jun;22(6):960-4 PubMed

Curr Med Res Opin. 2014 Jun;30(6):1109-19 PubMed

Arch Ophthalmol. 2010 Mar;128(3):312-8 PubMed

JAMA Intern Med. 2016 Oct 1;176(10 ):1464-1473 PubMed

Diabetes Obes Metab. 2013 Oct;15(10):938-53 PubMed

Diabetologia. 2015 Jan;58(1):1-3 PubMed

JAMA Intern Med. 2016 Oct 1;176(10 ):1-3 PubMed

PLoS Med. 2016 Jun 24;13(6):e1002091 PubMed

Lancet. 2005 Oct 8;366(9493):1279-89 PubMed

N Engl J Med. 2007 Jun 14;356(24):2457-71 PubMed

Eur J Clin Pharmacol. 2014 Nov;70(11):1277-89 PubMed

J Clin Endocrinol Metab. 2003 Feb;88(2):528-30 PubMed

Endocr Pract. 2011 May-Jun;17(3):e48-50 PubMed

Arch Intern Med. 2012 Jul 9;172(13):1005-11 PubMed

Diabetes Care. 2014 Sep;37(9):2647-59 PubMed

Diabetes Care. 2001 Jan;24(1):11-5 PubMed

Diabetes Obes Metab. 2015 Jun;17(6):523-32 PubMed

N Engl J Med. 2015 Dec 3;373(23 ):2247-57 PubMed

J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52 PubMed

Diabetologia. 2009 Sep;52(9):1699-708 PubMed

BMJ Open. 2012 Jul 13;2(4):null PubMed

N Engl J Med. 2006 Dec 7;355(23):2427-43 PubMed

Diabetes. 2013 Jul;62(7):2595-604 PubMed